Skip to main content

Sequenom Sells MassArray Instrument to Roswell Park Cancer Institute

NEW YORK, May 20 (GenomeWeb News) - Sequenom has sold a MassArray genotyping instrument to the Roswell Park Cancer Institute, the San Diego-based company said today.

 

The institute, based in Buffalo, NY, will initially use the system for pharmacogenomic studies in breast cancer patients to predict response to treatment, as well as to determine who is at risk for cardiovascular disese.

 

Sequenom's MassArray system analyzes DNA by mass spectrometry.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.